Asset Details
Do you wish to reserve the book?
Safety and efficacy of skin patches containing loxoprofen sodium in diabetic patients with overt nephropathy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Safety and efficacy of skin patches containing loxoprofen sodium in diabetic patients with overt nephropathy
Do you wish to request the book?
Safety and efficacy of skin patches containing loxoprofen sodium in diabetic patients with overt nephropathy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Safety and efficacy of skin patches containing loxoprofen sodium in diabetic patients with overt nephropathy
2014
Overview
Background
Because oral nonsteroidal anti-inflammatory drugs (NSAIDs) have adverse effects on kidney function, patients with kidney diseases are administered these drugs as transdermal patches. Little is known about the effects of NSAID patches on renal function. We therefore assessed the effects of topical loxoprofen sodium on kidney function in type 2 diabetic patients with overt nephropathy.
Methods
Twenty patients with type 2 diabetes and overt proteinuria and with knee and/or low back pain were treated with skin patches containing 100 mg loxoprofen on the knee or back for 24 h per day for 5 consecutive days. The degree of pain was assessed using a visual analogue scale (VAS). Blood and 24-h urine samples were obtained at baseline and at the end of the study. Glomerular filtration rate (GFR) was estimated from serum creatinine and cystatin C concentrations.
Results
The 20 patients consisted of 11 males and 9 females, of mean age 61.6 ± 13.9 years. Loxoprofen-containing patches significantly reduced VAS pain without affecting blood pressure, GFR or urinary prostaglandin E
2
concentration. Serum concentrations of loxoprofen and its active trans-OH metabolite did not correlate with GFR.
Conclusions
Loxoprofen-containing patches do not affect renal function in type 2 diabetic patients with overt nephropathy over a short-term period. Long-term studies are needed to clarify the safety of loxoprofen-containing patches in patients with chronic kidney diseases.
Publisher
Springer Japan,Springer Nature B.V
Subject
/ Aged
/ Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
/ Anti-Inflammatory Agents, Non-Steroidal - adverse effects
/ Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
/ Diabetes Mellitus, Type 2 - complications
/ Diabetic Nephropathies - blood
/ Diabetic Nephropathies - drug therapy
/ Diabetic Nephropathies - physiopathology
/ Dose-Response Relationship, Drug
/ Female
/ Glomerular Filtration Rate - physiology
/ Humans
/ Male
/ Medicine
/ Original
/ Phenylpropionates - administration & dosage
/ Phenylpropionates - adverse effects
/ Phenylpropionates - therapeutic use
/ Urology
